{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T12:46:50Z","timestamp":1784292410311,"version":"3.55.0"},"reference-count":37,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,4,12]],"date-time":"2021-04-12T00:00:00Z","timestamp":1618185600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81570163, 81873446, 81873427, 81700174, 81400147"],"award-info":[{"award-number":["81570163, 81873446, 81873427, 81700174, 81400147"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>We compared the effectiveness and safety of pegylated granulocyte colony-stimulating factor (peg-G-CSF) vs. non-peg-G-CSF for hematopoietic stem cell mobilization in allogeneic hematopoietic stem cell transplantation in a real-world setting. We included 136 consecutive healthy donors treated with non\u2013peg-G-CSF (n = 53) or peg-G-CSF (n = 83), and 125 consecutive recipients (n = 42 and 83, respectively) in this study. All harvesting was completed successfully. No significant difference in leukapheresis number and adverse events frequency was observed, nor were there severe adverse events leading to discontinuation of mobilization. The leukapheresis products mobilized by peg-G-CSF had higher total nucleated cells (p &amp;lt; 0.001), monocytic myeloid-derived suppressor cells (p &amp;lt; 0.001), granulocytic myeloid-derived suppressor cells (p = 0.004) and B cells (p = 0.019). CD34+ cells and other lymphocyte subsets (T cells, regulatory T cells, natural killer [NK] cells, etc.) were similar in both apheresis products. Patients who received grafts mobilized by peg-G-CSF exhibited a lower incidence of grade III-IV acute graft-versus-host disease (p = 0.001). The 1-year cumulative incidence of chronic graft-versus-host disease and relapse, 1-year probability of graft-versus-host disease-free relapse-free survival, and overall survival did not differ significantly between subgroups. Our results suggest that collecting allogeneic stem cells after the administration of peg-G-CSF is feasible and safe. Peg-G-CSF mobilized grafts may reduce severe acute graft-versus-host disease compared with non-peg-G-CSF mobilized grafts after allogeneic stem cell transplantation. The beneficial effects of a peg-G-CSF graft might be mediated by increased numbers of monocytic myeloid-derived suppressor cells.<\/jats:p>","DOI":"10.3389\/fimmu.2021.621935","type":"journal-article","created":{"date-parts":[[2021,4,12]],"date-time":"2021-04-12T07:30:04Z","timestamp":1618212604000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":7,"title":["Allogeneic Hematopoietic Stem Cell Transplantation Mobilized With Pegylated Granulocyte Colony-Stimulating Factor Ameliorates Severe Acute Graft-Versus-Host Disease Through Enrichment of Monocytic Myeloid-Derived Suppressor Cells in the Graft: A Real World Experience"],"prefix":"10.3389","volume":"12","author":[{"given":"Lin","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin","family":"Yin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yun","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunyan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xia","family":"Mao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Na","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinhuan","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yicheng","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2021,4,12]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.2000.02412.x","article-title":"A randomized comparison of once versus twice daily recombinant human granulocyte colony-stimulating factor (filgrastim) for stem cell mobilization in healthy donors for allogeneic transplantation","volume":"111","author":"Kr\u00f6ger","year":"2000","journal-title":"Br J Haematol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1701549","article-title":"Stem cell mobilization with G-CSF alone in breast cancer patients: higher progenitor cell yield by delivering divided doses (2 x 5 microg\/kg) compared to a single dose (1 x 10 microg\/kg)","volume":"23","author":"Kr\u00f6ger","year":"1999","journal-title":"Bone Marrow Transplant"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1702338","article-title":"Single vs twice daily G-CSF dose for peripheral blood stem cells harvest in normal donors and children with non-malignant diseases","volume":"25","author":"Lee","year":"2000","journal-title":"Bone Marrow Transplant"},{"key":"B4","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.2165\/00003495-200262080-00012","article-title":"Pegfilgrastim","volume":"62","author":"Curran","year":"2002","journal-title":"Drugs"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2002.20.3.727","article-title":"Blinded, randomized, multicenter study to evaluate single administration pegfilgrastim once per cycle versus daily filgrastim as an adjunct to chemotherapy in patients with high-risk stage II or stage III\/IV breast cancer","volume":"20","author":"Holmes","year":"2002","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2003.03.040","article-title":"Randomized, multicenter, open-label study of pegfilgrastim compared with daily filgrastim after chemotherapy for lymphoma","volume":"21","author":"Vose","year":"2003","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.2000.02252.x","article-title":"Efficient mobilization of haematopoietic progenitors after a single injection of pegylated recombinant human granulocyte colony-stimulating factor in mouse strains with distinct marrow-cell pool sizes","volume":"110","author":"de Haan","year":"2000","journal-title":"Br J Haematol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/j.exphem.2005.08.003","article-title":"Single-dose pegfilgrastim for the mobilization of allogeneic CD34+ peripheral blood progenitor cells in healthy family and unrelated donors","volume":"90","author":"Kroschinsky","year":"2005","journal-title":"Haematologica"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2006.03.001","article-title":"Allogeneic stem cell transplantation with peripheral blood stem cells mobilized by pegylated G-CSF","volume":"12","author":"Hill","year":"2006","journal-title":"Biol Blood Marrow Transplant J Am Soc Blood Marrow Transplant"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1704702","article-title":"Successful transplantation of peripheral blood stem cells mobilized by chemotherapy and a single dose of pegylated G-CSF in patients with multiple myeloma","volume":"35","author":"Steidl","year":"2005","journal-title":"Bone Marrow Transplant"},{"key":"B11","article-title":"Phase II study of a single pegfilgrastim injection as an adjunct to chemotherapy to mobilize stem cells into the peripheral blood of pretreated lymphoma patients","volume":"90","author":"Isidori","year":"2005","journal-title":"Haematologica"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1705459","article-title":"Efficacy of single dose pegfilgrastim in enhancing the mobilization of CD34+ peripheral blood stem cells in aggressive lymphoma patients treated with cisplatin-aracytin-containing regimens","volume":"38","author":"Nosari","year":"2006","journal-title":"Bone Marrow Transplant"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1172\/JCI25249","article-title":"NKT cell-dependent leukemia eradication following stem cell mobilization with potent G-CSF analogs","volume":"115","author":"Morris","year":"2005","journal-title":"J Clin Invest"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-08-2864","article-title":"Donor treatment with pegylated G-CSF augments the generation of IL-10-producing regulatory T cells and promotes transplantation tolerance","volume":"103","author":"Morris","year":"2004","journal-title":"Blood"},{"key":"B15","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1158\/2326-6066.CIR-16-0297","article-title":"Myeloid-Derived Suppressor Cells","volume":"5","author":"Gabrilovich","year":"2017","journal-title":"Cancer Immunol Res"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.688","article-title":"Circulating CD14(+) HLA-DR(-\/low) myeloid-derived suppressor cells in leukemia patients with allogeneic hematopoietic stem cell transplantation: novel clinical potential strategies\u00a0for the prevention and cellular therapy of graft-versus-host disease","volume":"5","author":"Yin","year":"2016","journal-title":"Cancer Med"},{"key":"B17","unstructured":"Common Terminology Criteria for Adverse Events v5.0"},{"key":"B18","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1016\/j.bbmt.2015.09.001","article-title":"International, Multicenter Standardization of Acute Graft-versus-Host Disease Clinical Data Collection: A Report from the Mount Sinai Acute GVHD International Consortium","volume":"22","author":"Harris","year":"2016","journal-title":"Biol Blood Marrow Transplant J Am Soc Blood Marrow Transplant"},{"key":"B19","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1016\/j.bbmt.2015.05.004","article-title":"National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2014 Diagnosis and Staging Working Group report","volume":"21","author":"Jagasia","year":"2015","journal-title":"Biol Blood Marrow Transplant J Am Soc Blood Marrow Transplant"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2011.050096","article-title":"Long-term follow up after allogeneic stem cell transplantation in patients with severe aplastic anemia after cyclophosphamide plus antithymocyte globulin conditioning","volume":"97","author":"Konopacki","year":"2012","journal-title":"Haematologica"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1086\/588660","article-title":"Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer\/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC\/MSG) Consensus Group","volume":"46","author":"De Pauw","year":"2008","journal-title":"Clin Infect Dis  Off Publ Infect Dis Soc America"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.00396","article-title":"Composite GRFS and CRFS Outcomes After Adult Alternative Donor HCT","volume":"38","author":"Mehta","year":"2020","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2003.12.011","article-title":"Evidence that the granulocyte colony-stimulating factor (G-CSF) receptor plays a role in the pharmacokinetics of G-CSF and PegG-CSF using a G-CSF-R KO model","volume":"50","author":"Kotto-Kome","year":"2004","journal-title":"Pharmacol Res"},{"key":"B24","doi-asserted-by":"publisher","first-page":"295","DOI":"10.2165\/11586040-000000000-00000","article-title":"Pharmacokinetics and pharmacodynamics of pegfilgrastim","volume":"50","author":"Yang","year":"2011","journal-title":"Clin Pharmacokinet"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1002\/jca.21550","article-title":"Pegylated granulocyte-colony stimulating factor versus non-pegylated granulocyte-colony stimulating factor for peripheral blood stem cell mobilization: A systematic review and meta-analysis","volume":"32","author":"Kuan","year":"2017","journal-title":"J Clin Apher"},{"key":"B26","doi-asserted-by":"publisher","first-page":"e00503","DOI":"10.1002\/prp2.503","article-title":"Pharmacokinetics, pharmacodynamics, safety, and immunogenicity of Pelmeg(\u00ae), a pegfilgrastim biosimilar in healthy subjects","volume":"7","author":"Roth","year":"2019","journal-title":"Pharmacol Res Perspect"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-01-624163","article-title":"In vitro-generated MDSCs prevent murine GVHD by inducing type 2 T cells without disabling antitumor cytotoxicity","volume":"126","author":"Messmann","year":"2015","journal-title":"Blood"},{"key":"B28","doi-asserted-by":"publisher","first-page":"E9","DOI":"10.1002\/ajh.23865","article-title":"Monocytic and promyelocytic myeloid-derived suppressor cells may contribute to G-CSF-induced immune tolerance in haplo-identical allogeneic hematopoietic stem cell transplantation","volume":"90","author":"Lv","year":"2015","journal-title":"Am J Hematol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2014.09.011","article-title":"Graft monocytic myeloid-derived suppressor cell content predicts the risk of acute graft-versus-host disease after allogeneic transplantation of granulocyte colony-stimulating factor-mobilized peripheral blood stem cells","volume":"20","author":"Vendramin","year":"2014","journal-title":"Biol Blood Marrow Transplant J Am Soc Blood Marrow Transplant"},{"key":"B30","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1186\/s13045-017-0503-2","article-title":"Superior GVHD-free, relapse-free survival for G-BM to G-PBSC grafts is associated with higher MDSCs content in allografting for patients with acute leukemia","volume":"10","author":"Fan","year":"2017","journal-title":"J Hematol Oncol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.12081","article-title":"Pegylated granulocyte colony-stimulating factor mobilizes CD34+ cells with different stem and progenitor subsets and distinct functional properties in comparison with unconjugated granulocyte colony-stimulating factor","volume":"93","author":"Bruns","year":"2008","journal-title":"Haematologica"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1007\/s12185-014-1507-0","article-title":"Successful peripheral blood stem cell mobilization using pegfilgrastim in allogeneic stem cell transplantation","volume":"99","author":"Chanswangphuwana","year":"2014","journal-title":"Int J Hematol"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2015.98","article-title":"Comparison of outcomes after unrelated cord blood and unmanipulated haploidentical stem cell transplantation in adults with acute leukemia","volume":"29","author":"Ruggeri","year":"2015","journal-title":"Leukemia"},{"key":"B34","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1002\/cac2.12014","article-title":"Haploidentical- versus identical-sibling transplant for high-risk pediatric AML: A multi-center study","volume":"40","author":"Zheng","year":"2020","journal-title":"Cancer Commun (London England)"},{"key":"B35","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1186\/s13045-017-0394-2","article-title":"A comparison between allogeneic stem cell transplantation from unmanipulated haploidentical and unrelated donors in acute leukemia","volume":"10","author":"Piemontese","year":"2017","journal-title":"J Hematol Oncol"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1517\/14712598.2014.895809","article-title":"Long-active granulocyte colony-stimulating factor for peripheral blood hematopoietic progenitor cell mobilization","volume":"14","author":"Martino","year":"2014","journal-title":"Expert Opin Biol Ther"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-10-4299","article-title":"Stem cell mobilization with G-CSF analogs: a rational approach to separate GVHD and GVL","volume":"107","author":"Morris","year":"2006","journal-title":"Blood"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2021.621935\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,12]],"date-time":"2021-04-12T07:30:54Z","timestamp":1618212654000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2021.621935\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4,12]]},"references-count":37,"alternative-id":["10.3389\/fimmu.2021.621935"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2021.621935","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,4,12]]},"article-number":"621935"}}